Evaluation of the effect of memantine on post herpetic neuralgia (PHN)

Study the effects of memantine on pain control and post herpetic neuralgia (PHN) in pateints with shingles; Double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180404039187N6

Enrollment

Registered

2020-01-31

Start date

2019-05-15

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Herpetic Neuralgia. Polyneuropathy, unspecified

Interventions

Intervention 1: Intervention group: Memantine 5 mg twice daily in the first week and then 10 mg twice daily upto 8 weeks along with Routin treatment (Tab Acetaminophen 500 mg up to 4 times a day and

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients aged 18 to 75 years Patients who have been suffering from painful rash for maximum 4 weeks in these patients and treated with herpes neuralgia medications

Exclusion criteria

Exclusion criteria: Patients with diabetes-induced neuropathy Patients with cardiovascular disease Patients with epilepsy Patients with hepatic failure

Design outcomes

Primary

Measure	Time frame
Change in heat and cold sensation. Timepoint: At the beginning and 8 weeks later. Method of measurement: Using a thermal probe.;Pain and numbness on the location of rash. Timepoint: At the beginning and 8 weeks later. Method of measurement: DN4 questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElnaz Shaseb

Tabriz University of Medical Sciences

Elnaz_shaseb_64@yahoo.com+98 41 3334 4198

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026